The Online Investor

Slideshow 25 Top Lowest PE Ratios in the S&P 500

By The Online Investor Staff, updated Sat., Mar. 25, 12:13 PM

#25. Moderna Inc (NASDAQ:MRNA) PE Ratio: 5.33

Moderna is a biotechnology company focusing on messenger RNA (mRNA) therapeutics and vaccines to create medicines. mRNA medicines are designed to direct the body's cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range of diseases. Co. is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, autoimmune diseases and cardiovascular diseases. Co. has a collaboration agreement with the Institute of Life Changing Medicines to develop a mRNA therapeutic (mRNA-3351) for Crigler-Najjar Syndrome Type 1.

MRNA SEC Filing Email Alerts Service

Open the MRNA Page at The Online Investor »

Company Name: 
Moderna Inc
Website: 
www.modernatx.com
Sector: 
Biotechnology
Number of ETFs Holding MRNA: 
109
Total Market Value Held by ETFs: 
$6.66B
Total Market Capitalization: 
$57.25B
% of Market Cap. Held by ETFs: 
11.63%

Open the MRNA Page at The Online Investor (in a new window) »

List of Low PE Ratio Stocks in this Slideshow: Company Ticker PE Ratio First Republic Bank (San Francisco, CA) FRC 1.61 DISH Network Corp DISH 2.42 APA Corp APA 3.13 American International Group Inc AIG 3.64 Principal Financial Group Inc PFG 3.80 Phillips 66 PSX 4.03 Organon & Co OGN 4.12 Zions Bancorporation, N.A. ZION 4.16 Mosaic Co (The) MOS 4.21 Marathon Oil Corp. MRO 4.21 CF Industries Holdings Inc CF 4.23 Citigroup Inc C 4.25 Valero Energy Corp VLO 4.45 Synchrony Financial SYF 4.56 Coterra Energy Inc CTRA 4.66 Comerica, Inc. CMA 4.77 Capital One Financial Corp COF 5.05 Diamondback Energy, Inc. FANG 5.10 Devon Energy Corp. DVN 5.11 PulteGroup Inc PHM 5.15 Nucor Corp. NUE 5.16 Steel Dynamics Inc. STLD 5.18 Discover Financial Services DFS 5.21 Goldman Sachs Group Inc GS 5.26 Moderna Inc MRNA 5.33
Quotes delayed 20 minutes

Email EnvelopeFree MRNA Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Buy (2.93 out of 4)
21st percentile
(ranked lower than approx. 79% of all stocks covered)

Analysts' Target Price:
MRNA Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Top 25 Lowest P/E Ratios of the S&P 500 Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2023, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.